多组学技术在脂肪性肝病不同阶段中的应用和研究进展

摘要/Abstract

摘要： 脂肪性肝病(SLD)发病率逐年攀升,其向肝纤维化、肝硬化乃至肝细胞癌等晚期肝病的进展严重威胁全球公共健康。现有临床诊断手段难以准确区分SLD不同疾病阶段,阻碍了早期诊断与精准治疗。多组学技术的兴起为揭示SLD发病机制、发现新型生物标志物提供了前所未有的机遇。本文综述了基因组学、转录组学、蛋白质组学、代谢组学、微生物组学、病毒组学和真菌组学等组学技术在SLD研究中的最新进展,并探讨了多组学研究在识别SLD不同疾病阶段中的作用。通过对海量组学数据的挖掘,有助于深入了解SLD的发病机制,发现不同阶段新的诊断标志物和治疗靶点,为实现SLD的精准医学提供科学依据。

蒋晶晶, 李青, 谢青, 赖荣陶. 多组学技术在脂肪性肝病不同阶段中的应用和研究进展[J]. 肝脏, 2024, 29(10): 1169-1172.

/ 推荐

参考文献

[1] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861.
[2] Emdin C A, Haas M, Ajmera V, et al. Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study [J]. Gastroenterology, 2021, 160(5): 1620-33 e13.
[3] Sveinbjornsson G, Ulfarsson M O, Thorolfsdottir R B, et al. Multiomics study of nonalcoholic fatty liver disease [J]. Nat Genet, 2022, 54(11): 1652-1663.
[4] Gellert-Kristensen H, Richardson T G, Davey Smith G, et al. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population [J]. Hepatology, 2020, 72(3): 845-856.
[5] Israelsen M, Juel H B, Detlefsen S, et al. Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis [J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1784-94 e9.
[6] De Vincentis A, Tavaglione F, Jamialahmadi O, et al. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores [J]. Clin Gastroenterol Hepatol, 2022, 20(3): 658-673.
[7] Atic A I, Thiele M, Munk A, et al. Circulating miRNAs associated with nonalcoholic fatty liver disease [J]. Am J Physiol Cell Physiol, 2023, 324(2): C588-C602.
[8] Zhang X, Mens M M J, Abozaid Y J, et al. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study [J]. Aliment Pharmacol Ther, 2021, 53(3): 432-442.
[9] Mott J L, Waidmann O, K?berle V, et al. Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis [J]. PLoS ONE, 2012, 7(9):e45652.
[10] Li P, Shan K, Liu Y, et al. CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway [J]. Dig Dis Sci, 2019, 64(1): 113-122.
[11] Liu C H, Jiang W, Zeng Q, et al. CircRNA-PI4KB Induces Hepatic Lipid Deposition in Non-Alcoholic Fatty Liver Disease by Transporting miRNA-122 to Extra-Hepatocytes [J]. Int J Mol Sci,2023,24(2)2023, 24(2):1297.
[12] da Silva Lima N, Fondevila M F, Novoa E, et al. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function [J]. J Hepatol, 2022, 76(1): 11-24.
[13] Sanyal A J, Williams S A, Lavine J E, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease [J]. J Hepatol, 2023, 78(4): 693-703.
[14] Govaere O, Hasoon M, Alexander L, et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures [J]. Nat Metab, 2023, 5(4): 572-578.
[15] Thiele M, Suvitaival T, Trost K, et al. Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis [J]. Gastroenterology, 2023, 164(7): 1248-1260.
[16] Luukkonen P K, Zhou Y, Sadevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease [J]. J Hepatol, 2016, 64(5): 1167-1175.
[17] Israelsen M, Kim M, Suvitaival T, et al. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication [J]. JHEP Rep, 2021, 3(5): 100325.
[18] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis [J]. Nature, 2014, 513(7516): 59-64.
[19] Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota [J]. Hepatology, 2016, 63(3): 764-775.
[20] Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 167-180.
[21] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease [J]. Hepatology, 2009, 49(6): 1877-1887.
[22] Bajaj J S, Reddy K R, O'Leary J G, et al. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis [J]. Gastroenterology, 2020, 159(5): 1715-1730.e12.
[23] Patel V C, Lee S, Mcphail M J W, et al. Rifaximin-alpha reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial [J]. J Hepatol, 2022, 76(2): 332-342.
[24] Lang S, Demir M, Martin A, et al. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease [J]. Gastroenterology, 2020, 159(5): 1839-1852.
[25] Jiang L, Lang S, Duan Y, et al. Intestinal Virome in Patients With Alcoholic Hepatitis [J]. Hepatology, 2020, 72(6): 2182-2196.
[26] Lang S, Duan Y, Liu J, et al. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis [J]. Hepatology, 2020, 71(2): 522-538.
[27] Bajaj J S, Liu E J, Kheradman R, et al. Fungal dysbiosis in cirrhosis [J]. Gut, 2018, 67(6): 1146-54.
[28] Perakakis N, Polyzos S A, Yazdani A, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study [J]. Metabolism, 2019, 101.